Antibiotic-resistant bacteria will kill millions in the coming decades. Can we fix the broken economic and research models that could produce new treatments?
From my cover story in the May 31, 2019, Newsweek
In January, Columbia University revealed that four patients at its Irving Medical Center in New York had been sick with an unusual version of E. coli , a common gut bacterium. 
Although the news largely escaped attention in the media, it ricocheted through the world of infectious disease experts. The Columbia E. coli had a mutation in a gene, MCR-1, that confers a terrifying attribute: imperviousness to colistin, the final-line-of-defense antibiotic for the bug. “We’re looking to the shelf for the next antibiotic, and there’s nothing there,” says Erica Shenoy, associate chief of the infection control unit at Massachusetts General Hospital….Read more
David H. Freedman 